Kellner Michael
University Hospital Hamburg-Eppendorf, Dept of Psychiatry and Psychotherapy, Anxiety Spectrum Disorders Unit, Hamburg, Germany.
Dialogues Clin Neurosci. 2010;12(2):187-97. doi: 10.31887/DCNS.2010.12.2/mkellner.
Knowledge of pharmacotherapeutic treatment options in obsessive-compulsive disorder (OCD) has grown considerably over the past 40 years. Serotonergic antidepressants, such as selective serotonin reuptake inhibitors (SSRls) and clomipramine, are the established pharmacologic first-line treatment of OCD. Medium to large dosages and acute treatment for at least 3 months are recommended until efficacy is assessed. In case of significant improvement, maintenance treatment is necessary, Unfortunately, about half of the patients do not respond sufficiently to oral serotonergic antidepressants; augmentation with atypical antipsychotics is an established second-line drug treatment strategy. Alternatives include intravenous serotonergic antidepressants and combination with or switch to cognitive behavioral psychotherapy. Remarkably, a considerable proportion of OCD patients still do not receive rational drug treatment. Novel research approaches, such as preliminary treatment studies with glutamatergic substances, and trials with further drugs, as well as needed aspects of future research, are reviewed.
在过去40年里,人们对强迫症(OCD)药物治疗方案的了解有了显著增长。血清素能抗抑郁药,如选择性5-羟色胺再摄取抑制剂(SSRI)和氯米帕明,是公认的强迫症一线药物治疗方法。建议使用中到大剂量,并进行至少3个月的急性治疗,直至评估疗效。如果有显著改善,则需要维持治疗。不幸的是,约一半的患者对口服血清素能抗抑郁药反应不佳;使用非典型抗精神病药进行增效治疗是一种既定的二线药物治疗策略。其他选择包括静脉注射血清素能抗抑郁药,以及与认知行为心理治疗联合使用或改用认知行为心理治疗。值得注意的是,相当一部分强迫症患者仍未接受合理的药物治疗。本文综述了新的研究方法,如使用谷氨酸能物质的初步治疗研究、对其他药物的试验,以及未来研究的必要方面。